以岭药业(002603) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached CNY 3,934,956,597.43, representing a 44.56% increase compared to CNY 2,721,951,194.99 in the same period last year[3] - Net profit attributable to shareholders was CNY 1,202,514,384.13, a significant increase of 148.29% from CNY 484,315,677.33 year-on-year[3] - The basic earnings per share rose to CNY 0.72, up 148.28% from CNY 0.29 in the previous year[3] - Total operating revenue for Q1 2023 reached CNY 3,934,956,597.43, a significant increase of 44.7% compared to CNY 2,721,951,194.99 in the same period last year[17] - Net profit for Q1 2023 was CNY 1,201,436,813.41, representing a year-on-year growth of 148.3% from CNY 483,506,718.16[18] - Earnings per share for Q1 2023 were CNY 0.72, up from CNY 0.29 in Q1 2022, indicating a substantial increase in profitability[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 18,246,700,806.38, an increase of 11.70% from CNY 16,336,112,689.27 at the end of the previous year[3] - Total liabilities increased to CNY 6,114,648,032.17 in Q1 2023, up from CNY 5,405,840,867.59 in the previous year, marking a rise of 13.1%[16] - The total non-current assets reached CNY 9,786,704,237.57, an increase from CNY 9,081,925,407.83 year-on-year, reflecting a growth of 7.7%[16] Cash Flow - The company's cash flow from operating activities decreased by 26.61% to CNY 400,342,932.75, down from CNY 545,481,950.73 in the same period last year[3] - The cash inflow from operating activities for the current period was CNY 3,722,327,089.52, an increase of 47.1% compared to CNY 2,529,899,387.91 in the previous period[20] - The net cash flow from operating activities decreased to CNY 400,342,932.75 from CNY 545,481,950.73, representing a decline of 26.5%[20] - The cash outflow from investing activities was CNY 2,407,993,111.75, significantly higher than CNY 165,483,895.60 in the previous period[21] - The net cash flow from investing activities was negative at CNY -1,464,282,378.84, compared to CNY -164,849,718.98 in the previous period[21] - Cash inflow from financing activities was CNY 200,000,000.00, down from CNY 699,902,000.00 in the previous period[21] - The net cash flow from financing activities improved to CNY 193,768,027.01 from CNY -112,615,463.58[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 257,051[10] - The largest shareholder, Yiling Pharmaceutical Technology Co., Ltd., holds 31.53% of the shares, totaling 526,775,963 shares[10] - The top ten shareholders include several individuals with significant stakes, including Wu Xiangjun with 20.81% and Wu Rui with 2.34%[10] Operational Efficiency - The company reported a gross profit margin of approximately 65.0% for Q1 2023, compared to 61.5% in the same quarter last year, showing improved operational efficiency[17] - Research and development expenses for Q1 2023 were CNY 164,844,076.56, slightly higher than CNY 158,060,812.51 in Q1 2022, indicating continued investment in innovation[17] Market and Product Development - The company has not disclosed any new product or technology developments in the current report[12] - There are no indications of market expansion or mergers and acquisitions mentioned in the current financial report[12] - The company plans to expand its market presence and invest in new product development to sustain growth momentum in the upcoming quarters[18] Inventory and Receivables - The company reported a 39.58% increase in inventory, reaching CNY 2,822,132,114.80, attributed to increased production scale[8] - Inventory levels rose significantly to ¥2,822,132,114.80 from ¥2,021,821,524.20, an increase of approximately 39.7%[14] - Accounts receivable increased to ¥1,938,660,386.86 from ¥1,726,806,702.36, reflecting a growth of about 12.2%[14]